4 citations
,
January 2010 in “International journal of trichology” Bexarotene gel shows promise as a new treatment for alopecia areata.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
3 citations
,
November 2024 in “Pediatric Dermatology” Selumetinib causes fewer and less severe skin issues in children than binimetinib.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
March 2024 in “International journal of molecular sciences” Three specific genetic variants cause severe skin issues in children with EBS, highlighting the need for early genetic screening.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
September 2017 in “Pediatric Dermatology” The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
January 2024 in “Wiadomości Lekarskie” Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
February 2006 in “Inpharma Weekly”
10 citations
,
September 1997 in “Molecular carcinogenesis” Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” August 2025 in “Pharmaceutics” A new method improves betulin delivery and shows promise in cancer treatment.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.